ClpP内肽酶调节剂的专利展望：2019年至今
Patenting perspective of modulators of ClpP endopeptidase: 2019-present
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:4.6
分区:医学2区 / 药物化学2区 药学2区
发表日期:2024 Nov
作者:
Zhenyu Wang, Liqing He, Ziheng Fan, Youfu Luo
DOI:
10.1080/13543776.2024.2404233
摘要
ClpP是一种高度保守的丝氨酸蛋白酶，在细菌和人线粒体中维持蛋白质稳态方面发挥关键作用。多项研究表明，ClpP作为药物靶点具有潜力，ClpP调节剂，包括抑制剂和激活剂，在治疗耐药细菌、恶性肿瘤和脂肪肝等多种疾病方面展现出前景。本综述总结了过去五年内与ClpP调节剂相关的专利，详细介绍其权利要求和治疗应用。专利信息来源包括欧洲专利局、中国专利局和美国专利局，相关研究文章则通过PubMed获取。关于ClpP调节剂的专利数量不断增加，反映出相关研究的进展。通过总结和梳理相关专利，旨在激发研究人员的兴趣，推动基于ClpP调节剂的有效药物研发。ClpP功能异常相关的疾病范围广泛，显示出ClpP调节剂具有广阔的治疗潜力。
Abstract
ClpP is a highly conserved serine protease that plays a crucial role in maintaining protein homeostasis in both bacterial cells and human mitochondria. Several studies have demonstrated the potential of ClpP as a drug target, with ClpP modulators, including both inhibitors and activators, showing promise in treating a range of conditions such as drug-resistant bacteria, malignant cancers, and fatty liver disease.This review provides an overview of patents related to ClpP modulators filed over the last five years, detailing their claims and therapeutic applications. The sources of patent information included databases of the European Patent Office, the China Patent Office and the U.S.A. patent Office, while relevant research articles were accessed through PubMed.The number of patents concerning ClpP modulators is on the rise, reflecting advancements in related research. By summarizing and outlining relevant patents, we aim to stimulate further interest among researchers, ultimately leading to the development of effective drugs based on ClpP modulators. The broad spectrum of diseases associated with ClpP dysfunction underscores the potential for ClpP modulators to address a wide range of therapeutic needs.